Surface Oncology Inc. Email Format

Biotechnology ResearchMassachusetts, United States51-200 Employees

Surface Oncology is a clinical-stage biotechnology company focused on immuno-oncology and the tumor microenvironment, aiming to develop next-generation therapies to empower the body's immune response against cancer. The company notes that first-generation checkpoint inhibitors benefit only a subset of patients, and its strategy targets multiple components of the immunosuppressive tumor milieu to broaden and sustain responses. Through an expert scientific advisory board and a rigorous antibody discovery program, Surface develops diverse, highly specific antibodies to probe TME biology and generate therapeutic candidates.

The company is based in Cambridge, Massachusetts, and operates with a mid-sized team within the biotechnology sector. Its work spans discovery and preclinical to clinical development, with a portfolio designed to engage components of both innate and adaptive immunity. In 2023 Surface Oncology merged with Coherus BioSciences, reflecting a notable corporate development in its recent history.

Get verified Surface Oncology Inc. emails free

Company overview Employee directory